- Home
- ORKA vs OPK Comparison
ORKA vs OPK Comparison
Compare ORKA & OPK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ORKA | OPK |
|---|---|---|
| Founded | 2004 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1B | 1.0B |
| IPO Year | 1997 | 2011 |
Fundamental Metrics
Financial Performance| Metric | ORKA | OPK |
|---|---|---|
| Price | $94.92 | $1.66 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 12 | 3 |
| Target Price | ★ $92.50 | $1.60 |
| AVG Volume (30 Days) | 723.7K | ★ 2.5M |
| Earning Date | 05-13-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $606,879,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $4.24 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $14.89 | $0.98 |
| 52 Week High | $115.52 | $1.73 |
Technical Indicators
Market Signals| Indicator | ORKA | OPK |
|---|---|---|
| Relative Strength Index (RSI) | 48.92 | 63.98 |
| Support Level | $83.25 | $1.12 |
| Resistance Level | $97.02 | $1.73 |
| Average True Range (ATR) | 4.77 | 0.07 |
| MACD | 0.05 | 0.00 |
| Stochastic Oscillator | 72.74 | 72.73 |
Price Performance
Historical ComparisonAbout ORKA Oruka Therapeutics Inc.
Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions.
About OPK OPKO Health Inc.
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.